Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
ELAN, 20% Increase in Ordinary Profit, Update Record High for Second Consecutive Term, Dividend Raised by 1 Yen
6099 ELAN Corporation 【J-GAAP】
Earnings ReportELAN Corporation <6099> [TSE Prime] announced its financial results after the market closed on February 4th (15:30). The consolidated ordinary profit for the fiscal year ended December 2025 increased by 18.1% from the previous period to 4.18 billion yen. For the fiscal year ending December 2026, the consolidated ordinary profit is expected to grow by 19.5% to 5.00 billion yen, marking the second consecutive term of record-high profits. This will be the seventeenth consecutive term of revenue growth.
At the same time, the company has decided to increase the dividend this fiscal year to 16 yen, an increase of 1 yen from the previous fiscal year.
In the most recent three-month period, from October to December (4Q), the consolidated ordinary profit increased 37.2% from the same period last year, reaching 1.15 billion yen. The operating profit margin improved from 6.7% in the same period last year to 8.4%.
Kabutan News
Actual Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Dec, 2023 | 41,425 | 3,665 | 3,681 | 2,518 | 41.7 | 13 | Feb 14, 2024 | J-GAAP |
| Dec, 2024 | 47,513 | 3,575 | 3,542 | 2,354 | 38.9 | 13 | Feb 10, 2025 | J-GAAP |
| Dec, 2025 | 55,448 | 4,272 | 4,184 | 2,767 | 45.8 | 15 | Feb 4, 2026 | J-GAAP |
| YoY | +16.7% | +19.5% | +18.1% | +17.5% | +17.5% |
Full Year Results vs. Previous Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Dec, 2025 Guidance | 59,000 | 4,720 | 4,740 | 3,090 | 51.1 | 15 | Feb 10, 2025 | J-GAAP |
| Dec, 2025 Results | 55,448 | 4,272 | 4,184 | 2,767 | 45.8 | 15 | Feb 4, 2026 | J-GAAP |
| Revision Rate | -6.0% | -9.5% | -11.7% | -10.5% | -10.4% |
Current Period Guidance
H1 Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Jan - Jun, 2025 | 26,840 | 2,075 | 2,048 | 1,367 | 22.6 | 0 | Aug 6, 2025 | J-GAAP |
| Jan - Jun, 2026 Guidance | 29,200 | 2,400 | 2,400 | 1,590 | 26.3 | 0 | Feb 4, 2026 | J-GAAP |
| YoY | +8.8% | +15.7% | +17.2% | +16.3% | +16.3% |
Current Period Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Dec, 2024 | 47,513 | 3,575 | 3,542 | 2,354 | 38.9 | 13 | Feb 10, 2025 | J-GAAP |
| Dec, 2025 | 55,448 | 4,272 | 4,184 | 2,767 | 45.8 | 15 | Feb 4, 2026 | J-GAAP |
| Dec, 2026 Guidance | 60,800 | 5,000 | 5,000 | 3,200 | 52.9 | 16 | Feb 4, 2026 | J-GAAP |
| YoY | +9.7% | +17.0% | +19.5% | +15.6% | +15.6% |
Quarterly Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Oct - Dec, 2024 | 12,666 | 844 | 845 | 522 | 8.6 | 6.7 | Feb 10, 2025 | J-GAAP |
| Jan - Mar, 2025 | 13,433 | 1,187 | 1,180 | 800 | 13.2 | 8.8 | May 2, 2025 | J-GAAP |
| Apr - Jun, 2025 | 13,407 | 888 | 868 | 567 | 9.4 | 6.6 | Aug 6, 2025 | J-GAAP |
| Jul - Sep, 2025 | 13,899 | 967 | 977 | 655 | 10.8 | 7.0 | Nov 7, 2025 | J-GAAP |
| Oct - Dec, 2025 | 14,709 | 1,230 | 1,159 | 745 | 12.3 | 8.4 | Feb 4, 2026 | J-GAAP |
| YoY | +16.1% | +45.7% | +37.2% | +42.7% | +42.8% |
Related Articles
WAKAMOTO PHARMA, Apr-Dec (Cumulative 3Q) Ordinary Profit Turns to Profit, Oct-Dec Ordinary Profit Turns to Profit
FUJI KYUKO, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 5%
Astellas Pharma, Net Income Forecast for the Fiscal Year Revised Upward by 39%, Highest in Seven Terms
TAKACHIHO KOHEKI , Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 7%
NISHIO HOLDINGS, Oct-Dec (1Q) Ordinary Profit Decreases by 8%
M3 Inc, Apr-Dec (Cumulative 3Q) Net Income Increases by 28%, Oct-Dec Net Income Increases by 24%
SANSHIN ELECTRONICS, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 22%
Naikai Zosen, Oct-Dec (3Q) Ordinary Profit Increases by 45%, Current Fiscal Year Dividend Revised Upward by 60 Yen
TAKAHASHI CURTAIN WALL, Ordinary Profit Forecast for Last Fiscal Year Turns to Profit, Exceeds Expectations
ROHM, Net Income Forecast for the Fiscal Year Revised Upward by 11%